(d) within how many time period the cases under 30-A of the aggrieved persons are reviewed, with reasons therefor; and

(e) with in how many much time period the aggrieved persons are informed on the action of (d) above?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (e) The employees referred to in the question were holding posts below the Board level. In respect of such employees, the authority competent to take a decision is the management of the company. According to the information furnished by Indian Drugs and Pharmaceuticals Ltd. (IDPL), one of the two employees namely, Shri Kamal Bhasin had made an appeal on his own. There is no specific provision for an appeal against an order passed under Rule 30-A of the IDPL CDA Rules, 1978, as the rule can be invoked only in specific circumstances and the decision is taken at the highest level of the undertaking after the prior scrutiny of a Screening Committee, and for reasons to be recorded in writing. The 'Appeal' made by the said emplpoyee is, therefore, inadmissible under the rules. An order passed under the IDPL CDA Rules, including Rule 30-A, can be reviewed in terms of the general provisions contained in Rule 33 of the said rules. No review petition has been received by IDPL from the affected employee.

Difference in prices of generic and brand names

2909. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that the prices of drug with generic names are substantially higher than these with brand names;

(b) if so, the reasons therefor;

(c) whether Government are also aware that many drug units, including some multinational have either switched over or are switching over to generic names from their own brand names; and

(d) if so, what are the names of such units and what action has been taken or is being taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Yes Sir. This has been observed in certain cases.

(b) As per the provisions of DPCO, 1987, single ingredient formulations, based on the bulk drugs specified in the second schedule and sold under generic name are exempt from price control.

(c) Yes Sir.

(d) Usage of generic name is not prohibited under DPCO, 1987. To the extent information is available details are given in the Statement enclosed.

Statement

Details of products being sold under Generic name at a price higher than the approved prices for branded products

Sl. No.	Name of the Product	Name of the Co/ics	Pack Size
1	Chloramphenicol Caps. 250mg.	Parke-Davis & Dey's Med. Store	10's Strip
2	Thioridazine Hel Tabs. 5mg.	Sandoz (I) Ltd.	(5×20)'s Strip.

1	2	3	4
3	Thioridazine Hol Tabs. 10mg.	Sandoz (I) Ltd.	(10×10)'s Strip.
4	Thioridazine Hel Tabs. 20mg.	Sandoz (I) Ltd.	(5×20)'s Strip.
5	Phenobarbitone Sod. 200mg.	Rhone-Poulanc	10×1 ml.
6	Tetracycline Eye Ointment.	Pfizer (I) Ltd.	3gm. Tube
7	Vitamin 'C'	E. Merck	10's Strip.
8	Prednisolone Tabs. 10mg	Wyeth Lab.	(10×10)'s Strip.
9	Prednisolone Tabs. 20mg	Wyeth Lab.	(10X6)'s Strip.
10	Hydrocortisone Sod. Succinate Inj. I.P. 134mg. (Equivalent to 100mg of Hydrocortisone)	Glaxo (I) Ltd.	3ml vial with 2ml Amp. of water for Inj. (Twin Pack).
11	Hydrocortisone Sod. Succinate Pellats 3.3mg. (equivalent to 2.5mg of Hydrocortisone).	Glaxo (I) Ltd.	1 vial×10's

Application on Rule 30-A of the IDPL/CDA Rules

2910. SHRIMATI SARALA MAHESHWARI: Will the PRIME MINISTER be pleased to refer to the replies given to the Unstarred Question Nos. 4622 and 2259 on 28-8-92 and 30-7-92 and state:

(a) when rule 30-A has been used prospectively on its employees by IDPL, if so, what happened to the period between 12-3-1989 and 11-3-91 together with reasons therefor.

(b) whether any definite order has been issued by IDPL for the period between 12-3-1989 and 11-3-1991, if not, the reasons therefor;

(c) whether the dues due during the above mentioned period have been paid by IDPL to the affected employees, if not, the reasons therefor; and

(d) what government propose to take action against IDPL in not complying with the statements of the Prime Minister given in the Parliament to the referred questions?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) The employees referred to in the question were holding posts below the Board level. The authority competent to take a decision in matters relating to such employees is the management of the company. The issues raised essentially pertain to the internal administration of the company. 10 Unstarred Questions in the 164th Session of Rajya Sabha and 3 questions in the 165th Session of Rajya Sabha have already been replied to on this subject matter.

According to the information furnished by Indian Drugs & Pharmaceuticals Limited (IDPL), the specific period between 12-3-89 and 11.3.91 related to the case of one Shri Kamal Bhasin, a former Marketing Executive only. The official, despite directions given by the IDPL management,